作为癌症的潜在目标的MCL-1:最近的进展,结构见解和SAR研究
Vishakha Sharma1, Ankush Kumar1
1Amity School of Pharmaceutical Sciences, Amity University Punjab, Mohali, India.
Bioorganic chemistry
|January 31, 2025
概括
骨髓细胞白血病-1 (Mcl-1) 是癌症存活的关键蛋白质,也是新药的点. 本综述详细介绍了异环抑制剂,它们的活性和临床状态,以帮助未来的抗癌药物设计.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 分子生物学分子生物学
背景情况:
- 骨髓细胞白血病-1 (Mcl-1) 是B细胞淋巴瘤2 (Bcl-2) 家族中的一种支持生存的蛋白质,对调节亡至关重要.
- 过度表达Mcl-1与各种癌症有关,使其成为抗癌药物发现的有效标.
- 由于其在癌细胞存活中的关键作用,Mcl-1抑制剂正在积极研究.
研究的目的:
- 审查Mcl-1抑制剂设计的最新进展.
- 巩固有关抗癌活性,结构-活性关系 (SAR) 和Mcl-1抑制剂分子建模的信息.
- 提供有关Mcl-1抑制剂临床试验状态的见解.
主要方法:
- 从2020年到现在出版的Mcl-1抑制剂的综合文献综述.
- 基于各种异环基架的抑制剂的分析,包括pyrrole,pyrazole,coumarin,quinoline和indole.
- 包括关于抗癌疗效,SAR,分子建模和临床进展的数据.
主要成果:
- 许多向Mcl-1的异环化合物已被合成并评估其抗癌活性.
- 详细的SAR研究和分子建模为抑制剂-标相互作用提供了洞察力.
- 虽然有前途,但迄今为止还没有任何Mcl-1抑制剂获得监管批准,这突显了未满足的临床需求.
结论:
- 异环化合物是开发新型Mcl-1抑制剂的丰富来源.
- 需要进一步的研究,专注于优化疗效,安全性和临床转化.
- 本综述对于设计下一代Mcl-1向治疗的研究人员来说是一个宝贵的资源.
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:23Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K